| 1 | SENATE BILL 39 |
|----|--|
| 2 | 57TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2025 |
| 3 | INTRODUCED BY |
| 4 | Elizabeth "Liz" Stefanics and Reena Szczepanski |
| 5 | and Mimi Stewart and Carrie Hamblen |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | AN ACT |
| 11 | RELATING TO INSURANCE; AMENDING THE PRIOR AUTHORIZATION ACT TO |
| 12 | ADD MORE CLASSES OF DRUGS THAT ARE NOT SUBJECT TO PRIOR |
| 13 | AUTHORIZATIONS OR STEP THERAPY PROTOCOLS. |
| 14 | |
| 15 | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO: |
| 16 | SECTION 1. Section 59A-22B-2 NMSA 1978 (being Laws 2019, |
| 17 | Chapter 187, Section 4) is amended to read: |
| 18 | "59A-22B-2. DEFINITIONSAs used in the Prior |
| 19 | Authorization Act: |
| 20 | A. "adjudicate" means to approve or deny a request |
| 21 | for prior authorization; |
| 22 | B. "auto-adjudicate" means to use technology and |
| 23 | automation to make a near-real-time determination to approve, |
| 24 | deny or pend a request for prior authorization; |
| 25 | C. "covered person" means an individual who is |
| | .230346.2GLG |

[bracketed material] = delete <u>underscored material = new</u>

1 insured under a health benefits plan;

"emergency care" means medical care, 2 D. 3 pharmaceutical benefits or related benefits to a covered person after the sudden onset of what reasonably appears to be a medical condition that manifests itself by symptoms of sufficient severity, including severe pain, that the absence of 7 immediate medical attention could be reasonably expected by a 8 reasonable layperson to result in jeopardy to a person's 9 health, serious impairment of bodily functions, serious 10 dysfunction of a bodily organ or part or disfigurement to a 11 person;

Ε. "health benefits plan" means a policy, contract, certificate or agreement, entered into, offered or issued by a health insurer to provide, deliver, arrange for, pay for or reimburse any of the costs of medical care, pharmaceutical benefits or related benefits;

"health care professional" means an individual F. who is licensed or otherwise authorized by the state to provide health care services;

"health care provider" means a health care G. professional, corporation, organization, facility or institution licensed or otherwise authorized by the state to provide health care services;

"health insurer" means a health maintenance н. organization, nonprofit health care plan, provider service .230346.2GLG

bracketed material] = delete underscored material = new

4

5

6

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 network, medicaid managed care organization or third-party
2 payer or its agent;

I. "medical care, pharmaceutical benefits or related benefits" means medical, behavioral, hospital, surgical, physical rehabilitation and home health services, and includes pharmaceuticals, durable medical equipment, prosthetics, orthotics and supplies;

J. "medical necessity" means health care services determined by a health care provider, in consultation with the health insurer, to be appropriate or necessary according to:

(1) applicable, generally accepted principlesand practices of good medical care;

(2) practice guidelines developed by the federal government or national or professional medical societies, boards or associations; or

(3) applicable clinical protocols or practice guidelines developed by the health insurer consistent with federal, national and professional practice guidelines, which shall apply to the diagnosis, direct care and treatment of a physical or behavioral health condition, illness, injury or disease;

K. "medical peer review" means review by a health care professional from the same or similar practice specialty that typically manages the medical condition, procedure or treatment under review for prior authorization;

- 3 -

.230346.2GLG

<u>underscored material = new</u> [bracketed material] = delete 8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

| 1 | L. "off-label" means a medication or a dosage of a | | |
|----|---|--|--|
| 2 | medication that is not approved by the federal food and drug | | |
| 3 | administration as a treatment for a specific condition or | | |
| 4 | disease but is prescribed to a covered person because there is | | |
| 5 | sufficient clinical evidence for a prescribing clinician to | | |
| 6 | reasonably consider the medication to be medically necessary to | | |
| 7 | treat the covered person's condition or disease; | | |
| 8 | $[L_{\cdot}]$ M. "office" means the office of superintendent | | |
| 9 | of insurance; | | |
| 10 | $[M_{\bullet}]$ N. "pend" means to hold a prior authorization | | |
| 11 | request for further clinical review; | | |
| 12 | [N.] <u>O.</u> "pharmacy benefits manager" means an agent | | |
| 13 | responsible for handling prescription drug benefits for a | | |
| 14 | health insurer; [and | | |
| 15 | 0.] <u>P.</u> "prior authorization" means a <u>voluntary or</u> | | |
| 16 | mandatory pre-service determination, including a recommended | | |
| 17 | clinical review, that a health insurer makes regarding a | | |
| 18 | covered person's eligibility for health care services, based on | | |
| 19 | medical necessity, the appropriateness of the site of services | | |
| 20 | and the terms of the covered person's health benefits plan; and | | |
| 21 | Q. "rare disease or condition" means a disease or | | |
| 22 | condition that affects fewer than two hundred thousand people | | |
| 23 | in the United States." | | |
| 24 | SECTION 2. Section 59A-22B-5 NMSA 1978 (being Laws 2019, | | |
| 25 | Chapter 187, Section 7) is amended to read: | | |
| | .230346.2GLG | | |
| | λ. | | |

<u>underscored material = new</u> [bracketed material] = delete

- 4 -

1 "59A-22B-5. PRIOR AUTHORIZATION REQUIREMENTS.--2 Α. A health insurer that [requires] offers prior 3 authorization shall: 4 use the uniform prior authorization forms (1) 5 developed by the office for medical care, for pharmaceutical benefits or related benefits pursuant to Section [6 of this 6 7 2019 act] 59A-22B-4 NMSA 1978 and for prescription drugs pursuant to Section 59A-2-9.8 NMSA 1978; 8 9 establish and maintain an electronic (2)10 portal system for: 11 (a) the secure electronic transmission 12 of prior authorization requests on a twenty-four-hour, seven-13 day-a-week basis, for medical care, pharmaceutical benefits or 14 related benefits; and 15 (b) [by January 1, 2021] auto-16 adjudication of prior authorization requests; 17 (3) provide an electronic receipt to the 18 health care provider and assign a tracking number to the health 19 care provider for the health care provider's use in tracking 20 the status of the prior authorization request, regardless of 21 whether or not the request is tracked electronically, through a 22 call center or by facsimile; 23 [by January 1, 2021] auto-adjudicate all (4) 24 electronically transmitted prior authorization requests to 25 approve or pend a request for benefits; and .230346.2GLG - 5 -

bracketed material] = delete

underscored material = new

1 accept requests for medical care, (5) pharmaceutical benefits or related benefits that are not 2 3 electronically transmitted. Prior authorization shall be deemed granted for 4 Β. 5 determinations not made within seven days; provided that: 6 (1)an adjudication shall be made within 7 twenty-four hours, or shall be deemed granted if not made 8 within twenty-four hours, when a covered person's health care 9 professional requests an expedited prior authorization and 10 submits to the health insurer a statement that, in the health 11 care professional's opinion that is based on reasonable medical 12 probability, delay in the treatment for which prior 13 authorization is requested could: 14 seriously jeopardize the covered (a) 15 person's life or overall health; 16 (b) affect the covered person's ability 17 to regain maximum function; or 18 (c) subject the covered person to severe 19 and intolerable pain; and 20 the adjudication time line shall commence (2) 21 only when the health insurer receives all necessary and 22 relevant documentation supporting the prior authorization 23 request. 24 After December 31, 2020, an insurer may C. 25 automatically deny a covered person's prior authorization .230346.2GLG

- 6 -

underscored material = new
[bracketed material] = delete

request that is electronically submitted and that relates to a prescription drug that is not on the covered person's health benefits plan formulary; provided that the insurer shall accompany the denial with a list of alternative drugs that are on the covered person's health benefits plan formulary.

D. Upon denial of a covered person's prior authorization request based on a finding that a prescription drug is not on the covered person's health benefits plan formulary, a health insurer shall notify the person of the denial and include in a conspicuous manner information regarding the person's right to initiate a drug formulary exception request and the process to file a request for an exception to the denial.

E. An auto-adjudicated prior authorization request based on medical necessity that is pended or denied shall be reviewed by a health care professional who has knowledge or consults with a specialist who has knowledge of the medical condition or disease of the covered person for whom the authorization is requested. The health care professional shall make a final determination of the request. If the request is denied after review by a health care professional, notice of the denial shall be provided to the covered person and covered person's provider with the grounds for the denial and a notice of the right to appeal and describing the process to file an appeal.

- 7 -

.230346.2GLG

<u>underscored material = new</u> [bracketed material] = delete 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

F. A health insurer shall establish a process by which a health care provider or covered person may initiate an electronic appeal of a denial of a prior authorization request.

G. A health insurer shall have in place policies and procedures for annual review of its prior authorization practices to validate that the prior authorization requirements advance the principles of lower cost and improved quality, safety and service.

H. The office [of superintendent of insurance] shall establish by rule protocols and criteria pursuant to which a covered person or a covered person's health care professional may request expedited independent review of an expedited prior authorization request made pursuant to Subsection B of this section following medical peer review of a prior authorization request pursuant to the Prior Authorization Act."

SECTION 3. Section 59A-22B-8 NMSA 1978 (being Laws 2023, Chapter 114, Section 13, as amended) is amended to read:

"59A-22B-8. PRIOR AUTHORIZATION FOR PRESCRIPTION DRUGS OR STEP THERAPY FOR CERTAIN CONDITIONS PROHIBITED.--

A. Coverage for medication approved by the federal food and drug administration that is prescribed for the treatment of an autoimmune disorder, cancer, <u>rare disease or</u> <u>condition</u> or a substance use disorder, pursuant to a medical necessity determination <u>made by a health care professional from</u> .230346.2GLG

<u>underscored material = new</u> [bracketed material] = delete 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

- 8 -

| 1 | the same or similar practice specialty that typically manages | | |
|----|---|--|--|
| 2 | the medical condition, procedure or treatment under review, | | |
| 3 | shall not be subject to prior authorization, except in cases in | | |
| 4 | which a biosimilar, interchangeable biologic or generic version | | |
| 5 | is available. <u>Medical necessity determinations shall be</u> | | |
| 6 | automatically approved within seven days for standard | | |
| 7 | determinations and twenty-four hours for emergency | | |
| 8 | determinations when a delay in treatment could: | | |
| 9 | <u>(1) seriously jeopardize a covered person's</u> | | |
| 10 | <u>life or overall health;</u> | | |
| 11 | (2) affect a covered person's ability to | | |
| 12 | <u>regain maximum function; or</u> | | |
| 13 | (3) subject a covered person to severe and | | |
| 14 | intolerable pain. | | |
| 15 | B. A health insurer shall not impose step therapy | | |
| 16 | requirements before authorizing coverage for medication | | |
| 17 | approved by the federal food and drug administration that is | | |
| 18 | prescribed for the treatment of an autoimmune disorder, cancer | | |
| 19 | or a substance use disorder, pursuant to a medical necessity | | |
| 20 | determination made by a health care professional from the same | | |
| 21 | or similar practice specialty that typically manages the | | |
| 22 | medical condition, procedure or treatment under review, except | | |
| 23 | in cases in which a biosimilar, interchangeable biologic or | | |
| 24 | generic version is available. | | |
| 25 | C. A health insurer shall not impose step therapy | | |

.230346.2GLG

<u>underscored material = new</u> [bracketed material] = delete

- 9 -

| 1 | requirements before authorizing coverage for an off-label | | | |
|----|--|--|--|--|
| 2 | medication that is prescribed for the treatment of a rare | | | |
| 3 | disease or condition, pursuant to a medical necessity | | | |
| 4 | determination made by a health care professional from the same | | | |
| 5 | or similar practice specialty that typically manages the | | | |
| 6 | medical condition, procedure or treatment under review, except | | | |
| 7 | <u>in cases in which a biosimilar, interchangeable biologic or</u> | | | |
| 8 | generic version is available. Medical necessity determinations | | | |
| 9 | shall be automatically approved within seven days for standard | | | |
| 10 | determinations and twenty-four hours for emergency | | | |
| 11 | determinations when a delay in treatment could: | | | |
| 12 | <u>(1) seriously jeopardize a covered person's</u> | | | |
| 13 | <u>life or overall health;</u> | | | |
| 14 | (2) affect a covered person's ability to | | | |
| 15 | <u>regain maximum function; or</u> | | | |
| 16 | (3) subject a covered person to severe and | | | |
| 17 | intolerable pain." | | | |
| 18 | SECTION 4. APPLICABILITYThe provisions of this act | | | |
| 19 | apply to an individual or group policy, contract, certificate | | | |
| 20 | or agreement to provide, deliver, arrange for, pay for or | | | |
| 21 | reimburse any of the costs of medical care, pharmaceutical | | | |
| 22 | benefits or related benefits that is entered into, offered or | | | |
| 23 | issued by a health insurer on or after July 1, 2025, pursuant | | | |
| 24 | to any of the following: | | | |
| 25 | A. Chapter 59A, Article 22 NMSA 1978; | | | |
| | 230346 2616 | | | |

.230346.2GLG

underscored material = new
[bracketed material] = delete

- 10 -

| | 1 | B. Chapter 59A, Article 23 NMSA 1978; |
|-----------------------------|----|---|
| | 2 | C. the Health Maintenance Organization Law; |
| | 3 | D. the Nonprofit Health Care Plan Law; or |
| | 4 | E. the Health Care Purchasing Act. |
| | 5 | - 11 - |
| | 6 | |
| | 7 | |
| | 8 | |
| | 9 | |
| | 10 | |
| | 11 | |
| | 12 | |
| | 13 | |
| | 14 | |
| | 15 | |
| | 16 | |
| ete | 17 | |
| <u>new</u> delete | 18 | |
| = = - | 19 | |
| eria rial | 20 | |
| <u>mat</u> | 21 | |
| red ed n | 22 | |
| rsco eket | 23 | |
| <u>underscored material</u> | 24 | |
| | 25 | |
| | | .230346.2GLG |